We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 538

Methods of medical treatment and dosage claims

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • June 28 2011

In Canada, claims to methods of medical treatment are considered to fall outside the definition of invention according to section 2 of the Patent Act and a decision of the Supreme Court of Canada

Court of Appeal again interprets utility requirement in Celebrex FCA

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 1 2014

The Federal Court of Appeal has again discussed the so-called “promise doctrine” in its October 30, 2014 decision of Apotex Inc. v. Pfizer Canada Inc

Competition Bureau sets out preliminary views on patent agreement settlement enforcement

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • October 27 2014

On September 23, 2014, John Pecman, the Commissioner of Competition, delivered the keynote address at the George Mason University Pharma Conference

The year in review: 2014 highlights in Canadian pharmaceutical IP and regulatory news

  • Smart & Biggar/Fetherstonhaugh
  • -
  • Canada
  • -
  • January 6 2015

The following are highlights of developments in Canadian pharmaceutical intellectual property and regulatory law in 2014

USPTO issues new subject matter guidance post-Myriad and Prometheus

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • March 7 2014

The United States Patent and Trademark Office (USPTO) issued a new guidance document for Examiners on March 4, 2014, effective immediately

“Gene Patent” controversy comes to Canada

  • Bereskin & Parr LLP
  • -
  • Canada, USA
  • -
  • November 4 2014

Patents related to isolated DNA corresponding to a gene, as well as methods claiming the diagnostic use of such DNA sequences are often referred to

Personalized medicine: patent issues in Canada and Europe

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, European Union
  • -
  • October 16 2014

Canada Introduction 'Personalized medicine', in its broadest aspects, is essentially the tailoring of treatments to individual characteristics, needs

Listing patents against combination drugs in Canada ? Changes coming

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • December 1 2014

On Nov. 26, 2014, Industry Canada announced an important proposed change to the eligibility requirements for listing a patent against a drug in

Federal Court upholds patent on Cellcept: found useful, non-obvious

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • July 21 2011

On July 13, 2011, Justice O’Reilly of the Federal Court granted an application commenced by Hoffmann-La Roche under the Patented Medicines (Notice of Compliance) Regulations to prohibit the Minister of Health from issuing a NOC to Apotex Inc. for its generic version of the brand drug, Cellcept (mycophenolate mofetil (“MMF”)), until the expiry of Hoffmann-La Roche’s Canadian Patent 1,333, 285

Supreme Court of Canada releases the Viagra decision

  • Osler Hoskin & Harcourt LLP
  • -
  • Canada
  • -
  • November 8 2012

In a unanimous decision released November 8, 2012, the Supreme Court of Canada has reversed the judgments of the Federal Court and the Federal Court of Appeal and cleared the way for an affordable generic version of Pfizer’s Viagra to be sold in Canada by Teva Canada Ltd